Plasma Rich in Growth Factors as an Adjuvant Agent in Non-Penetrating Deep Sclerectomy

Background: The purpose of this study is to evaluate the utility and safety of plasma rich in growth factors immunosafe eye drops (is-ePRGF) in the postoperative treatment of nonpenetrating deep sclerectomy (NPDS). Methods: This is a case-control study in patients with open-angle glaucoma. Group one (control) was not treated with is-ePRGF, while group two (is-ePRGF) was treated (four times a day for four months). Postoperative evaluations were performed at one day, one month, three months and six months. The main outcomes were: intraocular pressure (IOP), microcysts in blebs with AS-OCT and the number of hypotensive eye drops. Results: Preoperatively, group one (n = 48 eyes) and group two (n = 47 eyes) were similar in age (71.5 +/- 10.7 vs. 70.9 +/- 10.0 years; p = 0.68), IOP (20.6 +/- 10.2 vs. 23.0 +/- 9.0 mmHg; p = 0.26) and number of hypotensive drugs (2.7 +/- 0.8 vs. 2.8 +/- 0.9; p = 0.40). The IOP at six months dropped to 15.0 +/- 8.0 mmHg (IOP reduction: 27.2%) and 10.9 +/- 4.3 mmHg (IOP reduction: -52.6%) for group one and group two, respectively (p < 0.01). At six months, blebs with microcysts were 62.5% (group one) and 76.7% (group two). Postoperative complications were observed in 12 eyes (25%) for group one and in 5 eyes (11%) for group two (p = 0.06). No specific complications related to the use of is-ePRGF were identified. Conclusions: Topical is-ePRGF seems to reduce IOP and the rate of complications in the medium term after NPDS, so it can be considered as a possible safe adjuvant to achieve surgical success.

Automated summary

This study evaluated the utility and safety of plasma rich in growth factors immunosafe eye drops (is-ePRGF) in the postoperative treatment of nonpenetrating deep sclerectomy (NPDS). The results showed that the use of is-ePRGF can reduce intraocular pressure and the rate of complications, making it a possible safe adjuvant for surgical success.